Alemtuzumab

also known as CAMPATH 1H · Campath · MabCampath · ALLO-647 · CLLS52 · Alemtuzumab (Campath) · Campath-IH · alemtuzumab (Campath, Lemtrada) · +10 more

Monoclonal antibody targets CD52

Developed for: leukemia · B-cell chronic lymphocytic leukemia · myelodysplastic syndrome · lymphoma · sickle cell disease · chronic lymphocytic leukemia/small lymphocytic lymphoma · plasma cell myeloma · Hodgkins lymphoma
+124 more
· peripheral T-cell lymphoma, not otherwise specified · relapsing-remitting multiple sclerosis · acute myeloid leukemia · chronic myeloid leukemia · graft versus host disease · myelodysplastic/myeloproliferative disease · acute lymphoblastic leukemia · immunodeficiency disease · non-Hodgkin lymphoma · aplastic anemia · disease related to hematopoietic stem cell transplant · multiple sclerosis · type 1 diabetes mellitus · adult T-cell leukemia/lymphoma · hematopoietic and lymphoid cell neoplasm · paroxysmal nocturnal hemoglobinuria · plasma cell neoplasm · T-cell prolymphocytic leukemia · thalassemia · angioimmunoblastic T-cell lymphoma · beta thalassemia · chronic granulomatous disease · Diamond-Blackfan anemia · juvenile myelomonocytic leukemia · lymphoproliferative syndrome · myeloproliferative neoplasm · neuroblastoma · ovarian cancer · severe combined immunodeficiency · severe congenital neutropenia · T-cell non-Hodgkin lymphoma · Waldenstrom macroglobulinemia · Wiskott-Aldrich syndrome · acute undifferentiated leukemia · adult acute lymphoblastic leukemia · anaplastic large cell lymphoma · bone marrow failure syndrome · Burkitt lymphoma · Chediak-Higashi syndrome · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · common variable immunodeficiency · disease related to solid organ transplantation · extranodal nasal NK/T cell lymphoma · Fanconi anemia · grade III lymphomatoid granulomatosis · hairy cell leukemia · hemophagocytic syndrome · hepatosplenic T-cell lymphoma · hyper-IgM syndrome · immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome · inborn errors of metabolism · Langerhans cell histiocytosis · large-cell immunoblastic lymphoma · liver disorder · lymphoblastic lymphoma · MALT lymphoma · mantle cell lymphoma · mycosis fungoides · mycosis fungoides and variants · myelofibrosis · nodal marginal zone B-cell lymphoma · Sezary syndrome · Shwachman-Diamond syndrome · splenic marginal zone lymphoma · T-cell adult acute lymphocytic leukemia · T-cell large granular lymphocyte leukemia · transplant rejection · X-linked lymphoproliferative syndrome · acquired aplastic anemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute promyelocytic leukemia · acute transplant rejection · anemia · atypical chronic myeloid leukemia, BCR-ABL1 negative · autoimmune hemolytic anemia · autoimmune lymphoproliferative syndrome · autoimmune thrombocytopenic purpura · benign neoplasm · beta-thalassemia major · Bruton-type agammaglobulinemia · childhood myelodysplastic syndrome · chronic graft versus host disease · classic Hodgkin lymphoma · congenital amegakaryocytic thrombocytopenia · Crohn disease · diffuse large B-cell lymphoma · DiGeorge syndrome · Epstein-Barr virus infection · fallopian tube cancer · granulomatosis with polyangiitis · hemoglobinopathy · hemolytic anemia · high grade B-cell lymphoma · histiocytosis · Hoyeraal-Hreidarsson syndrome · hyper-IgM syndrome type 1 · idiopathic aplastic anemia · immune dysregulation, autoimmunity, and autoinflammation · inclusion body myositis · intraocular lymphoma · kidney cancer · leukocyte adhesion deficiency · mast cell leukemia · microscopic polyangiitis · myeloproliferative neoplasm, unclassifiable · peritoneum cancer · polyneuropathy, inflammatory demyelinating, chronic · precursor lymphoblastic lymphoma/leukemia · premalignant hematological system disease · primary cutaneous B-cell lymphoma · primary cutaneous T-cell lymphoma · primary cutaneous T-cell non-Hodgkin lymphoma · pure red-cell aplasia · renal cell carcinoma · Revesz syndrome · rheumatoid arthritis · small intestine lymphoma · systemic lupus erythematosus · systemic sclerosis · testicular lymphoma · vasculitis · end stage renal failure
Investigated by: National Cancer Institute (NCI) · Genzyme, a Sanofi Company · Bayer · M.D. Anderson Cancer Center · National Heart, Lung, and Blood Institute (NHLBI) · Baylor College of Medicine
+153 more
· Northwestern University · The Methodist Hospital Research Institute · German CLL Study Group · Masonic Cancer Center, University of Minnesota · University of Wisconsin, Madison · Center for Cell and Gene Therapy, Baylor College of Medicine · Dana-Farber Cancer Institute · Mayo Clinic · Fred Hutchinson Cancer Center · University of Chicago · Allogene Therapeutics · National Institute of Allergy and Infectious Diseases (NIAID) · Astellas Pharma Inc · Cancer Research UK · Case Comprehensive Cancer Center · Children's Hospital Medical Center, Cincinnati · Columbia University · David Rizzieri, MD · Hospital Universitario Dr. Jose E. Gonzalez · Immune Tolerance Network (ITN) · Spanish Lymphoma Cooperative Group · University of Alberta · University of Miami · Alliance for Clinical Trials in Oncology · Assistance Publique - Hôpitaux de Paris · Beth Israel Deaconess Medical Center · CABYC · Children's Hospital of Philadelphia · City of Hope Medical Center · Dr. Claudia Bösmüller · Eastern Cooperative Oncology Group · GlaxoSmithKline · Johns Hopkins University · Juvenile Diabetes Research Foundation · Karolinska University Hospital · Massachusetts General Hospital · National Comprehensive Cancer Network · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Marrow Donor Program · Nationwide Children's Hospital · New York Medical College · Northwell Health · Ohio State University Comprehensive Cancer Center · Study Group of Medical Tumour Therapy (AGMT) · University of Arizona · University of California, Los Angeles · University of California, San Francisco · University of Cologne · University of Göttingen · Washington University School of Medicine · Aarhus University Hospital · Alberta Children's Hospital · Alberta Innovates Health Solutions · Allan D Kirk, MD, PhD · American Society of Transplant Surgeons · Ann & Robert H Lurie Children's Hospital of Chicago · Arizona Oncology Associates · Astex Pharmaceuticals, Inc. · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Berlex Laboratories, Inc. · Blood and Marrow Transplant Clinical Trials Network · Boston Children's Hospital · Brigham and Women's Hospital · Bristol-Myers Squibb · Cambridge University Hospitals NHS Foundation Trust · Carelon Research · Central Texas Neurology Consultants · Cephalon · Charite University, Berlin, Germany · Children's Hospital Los Angeles · Children's Hospital at Montefiore · Children's Mercy Hospital Kansas City · Chronic Lymphocytic Leukemia Research Consortium · Clinical Trials in Organ Transplantation · all 159 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (3)	US (FDA)	LEMTRADA	—	2007-09-19 – 2018-11-28	fda.gov ↗
Approved	EU (EMA)	MabCampath	—	2001-07-06	europa.eu ↗
Approved	US (FDA)	LEMTRADA	—	2001-05-07	fda.gov ↗

Trials 223 · started per year

today

US approved 2001

EU approved 2001

199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT02653196	Sep 2015 → Aug 2017	neuroepithelial neoplasm	Montefiore Medical Center	Terminated	No outcome recorded
Phase 0	NCT00426517	Jan 2007 → Nov 2019	immunodeficiency disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 122 trials
Phase 1	NCT05384756	Jul 2022 → Dec 2026 expected	sickle cell disease	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 1	NCT04696731	Feb 2021 → Jan 2030 expected	clear cell renal carcinoma	Allogene Therapeutics	Active not recruiting	No outcome recorded
Phase 1	NCT03989466	Jan 2020 → Sep 2024	T-cell prolymphocytic leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT03939026	May 2019 → Oct 2021	large B-cell lymphoma	Allogene Therapeutics	Completed	No outcome recorded
Phase 1	NCT03132584	Jul 2017 → Jan 2018	high grade B-cell lymphoma	Dana-Farber Cancer Institute	Terminated	No outcome recorded
Phase 1	NCT02689453	Jan 2017 → Jun 2021	T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT02583594	Dec 2015 → Mar 2016	multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 1	NCT01624714	Sep 2012 → Apr 2017	multiple sclerosis	Samuel Forrester Hunter, MD, PhD	Unknown	No outcome recorded
Phase 1	NCT00923182	Feb 2010 → Aug 2011	B-cell chronic lymphocytic leukemia	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 1	NCT00947388	Nov 2008 → Sep 2012	chronic lymphocytic leukemia/small lymphocytic lymphoma	Case Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 1	NCT00637390	Mar 2008 → Oct 2010	fallopian tube cancer, ovarian cancer, peritoneum cancer	University of Michigan Rogel Cancer Center	Terminated	No outcome recorded
Phase 1	NCT00684255	Aug 2007 → Jul 2008	systemic lupus erythematosus, systemic sclerosis	New York Medical College	Terminated	No outcome recorded
Phase 1	NCT00495755	Jul 2007 → Oct 2011	chronic graft versus host disease	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1	NCT00562068	May 2007 → May 2009	lymphoma, small intestine cancer	Cancer Research UK	Unknown	No outcome recorded
Phase 1	NCT00458250	Sep 2006 → Feb 2008	acute lymphoblastic leukemia, acute myeloid leukemia	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 1	NCT00330252	May 2006 → Jan 2013	chronic lymphocytic leukemia/small lymphocytic lymphoma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1	NCT00214214	Oct 2005 → ?	type 1 diabetes mellitus	University of Wisconsin, Madison	Withdrawn	No outcome recorded
Phase 1	NCT00161590	Jul 2004 → ?	T-cell non-Hodgkin lymphoma	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 1	NCT00323323	Mar 2004 → Aug 2012	non-Hodgkin lymphoma	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT00113048	Dec 2003 → Sep 2005	hematopoietic and lymphoid cell neoplasm	Genzyme, a Sanofi Company	Terminated	No outcome recorded
Phase 1	NCT00278512	Aug 2003 → Jun 2016	vasculitis	Northwestern University	Terminated	No outcome recorded
Phase 1	NCT00282412	Sep 2002 → Jun 2016	rheumatoid arthritis	Northwestern University	Terminated	No outcome recorded

Phase 1/235 trials
Phase 1/2	NCT07599176	Jul 2026 → Jun 2032 expected	beta thalassemia, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 1/2	NCT05000450	Jun 2021 → Oct 2023	refractory plasma cell neoplasm	Allogene Therapeutics	Terminated	No outcome recorded
Phase 1/2	NCT03182426	Aug 2017 → Jul 2024	type 1 diabetes mellitus	University of Alberta	Completed	No outcome recorded
Phase 1/2	NCT03077542	Apr 2017 → Jul 2023 overdue	sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT02472054	Jun 2015 → Sep 2019	hemophagocytic syndrome	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 1/2	NCT02061800	Jun 2013 → Jul 2026 overdue	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia +1	Diane George	Active not recruiting	No outcome recorded
Phase 1/2	NCT01269385	Jan 2011 → Jun 2014	B-cell chronic lymphocytic leukemia	Mayo Clinic	Completed	No outcome recorded
Phase 1/2	NCT00983528	Sep 2009 → Sep 2011	acute lymphoblastic leukemia	University of California, San Diego	Terminated	No outcome recorded
Phase 1/2	NCT00935792	Jul 2009 → Dec 2015	B-cell chronic lymphocytic leukemia	Mayo Clinic	Completed	No outcome recorded
Phase 1/2	NCT00951457	Mar 2009 → Aug 2012	B-cell chronic lymphocytic leukemia	Study Group of Medical Tumour Therapy (AGMT)	Completed	No outcome recorded
Phase 1/2	NCT02435901	Dec 2008 → Mar 2019	beta-thalassemia major, sickle cell disease	Northwell Health	Completed	No outcome recorded
Phase 1/2	NCT00520130	Oct 2007 → Oct 2015	Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00579137	Oct 2007 → Oct 2009	Wiskott-Aldrich syndrome, severe combined immunodeficiency	Baylor College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00801931	Sep 2007 → May 2009	anemia, immunodeficiency disease, leukemia, lymphoma +1	Columbia University	Terminated	No outcome recorded
Phase 1/2	NCT00555048	Sep 2007 → Oct 2010	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Fred Hutchinson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT00579111	Jun 2007 → Feb 2009	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoproliferative syndrome +2	Baylor College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00773149	Oct 2006 → Jan 2011	acute lymphoblastic leukemia	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 1/2	NCT00453427	Sep 2006 → Jun 2013	peripheral T-cell lymphoma, not otherwise specified	Ontario Clinical Oncology Group (OCOG)	Completed	No outcome recorded
Phase 1/2	NCT00363090	Sep 2006 → Dec 2010	lymphoma	Toronto Sunnybrook Regional Cancer Centre	Unknown	No outcome recorded
Phase 1/2	NCT00085449	May 2006 → Jan 2007	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm	Alliance for Clinical Trials in Oncology	Withdrawn	No outcome recorded
Phase 1/2	NCT00943592	Mar 2006 → Apr 2011	leukemia, premalignant hematological system disease	University of Chicago	Completed	No outcome recorded
Phase 1/2	NCT00061568	Jul 2004 → Jan 2023	hemolytic anemia, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Unknown	No outcome recorded
Phase 1/2	NCT00167661	Jun 2004 → Dec 2011	disease related to solid organ transplantation	University of Wisconsin, Madison	Terminated	No outcome recorded
Phase 1/2	NCT00077961	Dec 2003 → Feb 2006	non-Hodgkin lymphoma	Genzyme, a Sanofi Company	Terminated	No outcome recorded
Phase 1/2	NCT00634881	Nov 2003 → Jan 2010	chronic lymphocytic leukemia/small lymphocytic lymphoma	German CLL Study Group	Completed	No outcome recorded
Phase 1/2	NCT00078559	Nov 2003 → Feb 2010	kidney disorder	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 1/2	NCT00061945	Jun 2003 → Dec 2007	B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00051701	Dec 2002 → Aug 2005	non-Hodgkin lymphoma	Genzyme, a Sanofi Company	Terminated	No outcome recorded
Phase 1/2	NCT00056966	Nov 2002 → May 2005	hematopoietic and lymphoid cell neoplasm	Baylor College of Medicine	Completed	No outcome recorded
Phase 1/2	NCT00047060	Jul 2002 → Jan 2019	Sezary syndrome, mycosis fungoides	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 1/2	NCT00056979	Jun 2002 → Jun 2003	inborn errors of metabolism	Baylor College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00590460	Jul 2001 → Sep 2009	Fanconi anemia	Baylor College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00048399	Dec 2000 → Oct 2003	disease related to hematopoietic stem cell transplant	Baylor College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00058825	Aug 2000 → Sep 2014	hematopoietic and lymphoid cell neoplasm	Baylor College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00048412	Jun 2000 → Nov 2004	leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, plasma cell myeloma	Baylor College of Medicine	Completed	No outcome recorded

Phase 2117 trials
Phase 2	NCT06872333	Nov 2024 → Jun 2030 expected	disease related to hematopoietic stem cell transplant, sickle cell disease	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05714345	Nov 2023 → Feb 2024	large B-cell lymphoma	Allogene Therapeutics	Terminated	No outcome recorded
Phase 2	NCT05501756	Jan 2023 → Aug 2028 expected	disease related to hematopoietic stem cell transplant	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2	NCT04154735	Nov 2019 → Mar 2023	Crohn disease	Northwestern University	Withdrawn	No outcome recorded
Phase 2	NCT03579875	Nov 2018 → Jan 2027 expected	Fanconi anemia, TCR-alpha-beta-positive T-cell deficiency, bone marrow failure syndrome, dyskeratosis congenita +2	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT03587272	Apr 2018 → Nov 2030 expected	sickle cell disease	Robert Nickel	Recruiting	No outcome recorded
Phase 2	NCT02385110	Sep 2015 → Jan 2023	leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT02171104	Jul 2014 → Jan 2026 overdue	Hurler syndrome, Krabbe disease, Niemann-Pick disease type B, Niemann-Pick disease, type C2 +15	Masonic Cancer Center, University of Minnesota	Active not recruiting	No outcome recorded
Phase 2	NCT02105766	Apr 2014 → Dec 2023 overdue	graft versus host disease, sickle cell disease, thalassemia	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 2	NCT02013375	Apr → May 2014	sickle cell disease	Damiano Rondelli, MD	Terminated	No outcome recorded
Show all 117 trials opens the full record — a long page
Phase 2/35 trials
Phase 2/3	NCT01120028	Sep 2010 → Feb 2014	—	University of Oxford	Completed	No outcome recorded
Phase 2/3	NCT00749112	Aug 2008 → Aug 2010	autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura	Hospital Universitario Dr. Jose E. Gonzalez	Completed	No outcome recorded
Phase 2/3	NCT00454480	Aug 2006 → Aug 2012	leukemia, myelodysplastic syndrome	The University of New South Wales	Completed	No outcome recorded
Phase 2/3	NCT00354120	Mar 2005 → Aug 2011	acute myeloid leukemia, chronic myeloid leukemia, lymphoproliferative syndrome, myelodysplastic syndrome +2	Italian Group for Bone Marrow Transplantation	Completed	No outcome recorded
Phase 2/3	NCT00176852	Jun 2002 → Mar 2014	Diamond-Blackfan anemia, Shwachman-Diamond syndrome, severe congenital neutropenia, sickle cell disease +1	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 312 trials
Phase 3	NCT01333358	May 2011 → Dec 2013	multiple sclerosis	Central Texas Neurology Consultants	Unknown	No outcome recorded
Phase 3	NCT01307332	Mar 2011 → Sep 2018	relapsing-remitting multiple sclerosis	University of British Columbia	Completed	No outcome recorded
Phase 3	NCT00930553	Aug 2009 → Feb 2016	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00646854	Jun 2008 → Dec 2016	peripheral T-cell lymphoma, not otherwise specified	Aarhus University Hospital	Completed	No outcome recorded
Phase 3	NCT00725231	Feb 2008 → Mar 2014	angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified	University of Göttingen	Unknown	No outcome recorded
Phase 3	NCT00548405	Oct 2007 → Sep 2011	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00530348	Aug 2007 → Apr 2011	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00316810	Apr 2006 → Feb 2011	—	Dr. Claudia Bösmüller	Completed	No outcome recorded
Phase 3	NCT00086580	Jul 2004 → Jun 2010	B-cell chronic lymphocytic leukemia	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00226512	Jul 2004 → ?	acute myeloid leukemia, myelodysplastic syndrome	Hadassah Medical Organization	Withdrawn	No outcome recorded
Phase 3	NCT00147381	Jan 2004 → Aug 2008	—	Dr. Claudia Bösmüller	Completed	No outcome recorded
Phase 3	NCT00046683	Jul 2001 → Jun 2006	B-cell chronic lymphocytic leukemia	Genzyme, a Sanofi Company	Completed	No outcome recorded

Phase 415 trials
Phase 4	NCT03535298	Jan 2019 → Jul 2027 expected	relapsing-remitting multiple sclerosis	The Cleveland Clinic	Active not recruiting	No outcome recorded
Phase 4	NCT03135249	May 2018 → Nov 2020	multiple sclerosis	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT02419378	Jun 2015 → Jul 2020	relapsing-remitting multiple sclerosis	University Hospital Muenster	Completed	No outcome recorded
Phase 4	NCT02255656	Jan 2015 → Jul 2020	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT02205489	Oct 2014 → Apr 2016	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01757574	Nov 2012 → Aug 2016	polyneuropathy, inflammatory demyelinating, chronic	Johns Hopkins University	Withdrawn	No outcome recorded
Phase 4	NCT01729494	Sep 2012 → Dec 2018	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT01395316	Jun 2011 → Oct 2015	multiple sclerosis	University of Chicago	Completed	No outcome recorded
Phase 4	NCT01405807	Feb 2011 → Mar 2014	granulomatosis with polyangiitis, microscopic polyangiitis	Cambridge University Hospitals NHS Foundation Trust	Unknown	No outcome recorded
Phase 4	NCT01213329	Feb 2006 → Apr 2009	—	Northwestern University	Terminated	No outcome recorded
Phase 4	NCT01172418	Feb 2006 → May 2010	—	University of Miami	Completed	No outcome recorded
Phase 4	NCT00113269	May 2005 → Mar 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT00177138	Jul 2004 → Nov 2006	diabetes mellitus	University of Minnesota	Terminated	No outcome recorded
Phase 4	NCT00685061	Nov 2002 → Sep 2004	—	University of Miami	Completed	No outcome recorded
Phase 4	NCT00681343	Sep 2002 → Oct 2006	—	University of Miami	Completed	No outcome recorded

Phase not applicable15 trials
—	NCT03302754	Oct 2017 → Mar 2019	disease related to hematopoietic stem cell transplant	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
—	NCT02179359	Sep 2014 → Nov 2024	Diamond-Blackfan anemia, Glanzmann thrombasthenia, Shwachman-Diamond syndrome, paroxysmal nocturnal hemoglobinuria +3	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT01652092	Sep 2012 → Dec 2025 overdue	Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, Omenn syndrome +6	Masonic Cancer Center, University of Minnesota	Active not recruiting	No outcome recorded
—	NCT01408342	Jul 2011 → Jan 2013	aplastic anemia	Hospital Universitario Dr. Jose E. Gonzalez	Withdrawn	No outcome recorded
—	NCT01042509	Oct 2009 → Oct 2011	graft versus host disease	Hospital Universitario Dr. Jose E. Gonzalez	Completed	No outcome recorded
—	NCT00619528	Jan 2008 → Jul 2022	immunodeficiency disease, transplant rejection	Northwestern University	Completed	No outcome recorded
—	NCT00336206	Jul 2006 → Oct 2009	B-cell chronic lymphocytic leukemia	Tawam Hospital	Unknown	No outcome recorded
—	NCT00579592	Apr 2006 → Mar 2007	acute transplant rejection	University of Wisconsin, Madison	Terminated	No outcome recorded
—	NCT00587847	Aug 2005 → Nov 2009	B-cell chronic lymphocytic leukemia	Northwell Health	Terminated	No outcome recorded
—	NCT00582894	Feb 2005 → Mar 2008	disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm	University of Oklahoma	Completed	No outcome recorded
—	NCT00525876	Jan 2005 → Sep 2010	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00073879	Apr 2003 → Apr 2004	kidney cancer	Baylor College of Medicine	Completed	No outcome recorded
—	NCT00038844	Jun 2001 → Dec 2007	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00038883	Apr 2001 → May 2006	T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
—	NCT00021151	Jan 2000 → Apr 2001	leukemia	Case Comprehensive Cancer Center	Completed	No outcome recorded

Also used as a comparator or background therapy in 98 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT03910452 Background	Oct 2019 → Jun 2034 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Active not recruiting	No outcome recorded
Phase 0	NCT03421756 Background	Mar → Sep 2018	sickle cell disease	Kathleen Dorritie	Terminated	No outcome recorded
Phase 0	NCT00881556 Background	Aug 2009 → Sep 2015	epidermolysis bullosa	Columbia University	Terminated	No outcome recorded
Phase 114 trials
Phase 1	NCT07015684 Background	Apr 2025 → Mar 2030 expected	sickle cell disease	Columbia University	Recruiting	No outcome recorded
Phase 1	NCT04093596 Background	Sep 2019 → Jan 2025	refractory plasma cell neoplasm	Allogene Therapeutics	Completed	No outcome recorded
Phase 1	NCT03504241 Background	Jul 2018 → Sep 2023	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT03190278 Background	Jun 2017 → Dec 2024 overdue	acute myeloid leukemia	Cellectis S.A.	Active not recruiting	No outcome recorded
Phase 1	NCT02867800 Background	Jul 2016 → Dec 2021	graft versus host disease, sickle cell disease	Monica Bhatia	Completed	No outcome recorded
Phase 1	NCT02678143 Background	Apr 2016 → Apr 2020	sickle cell disease	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT02165007 Background	Jan 2015 → Jan 2024	sickle cell-beta-thalassemia disease syndrome, thalassemia	Catherine Bollard	Completed	No outcome recorded
Phase 1	NCT01625351 Background	Aug 2012 → Feb 2020	Ewing sarcoma, Wilms tumor, clear cell adenocarcinoma, germ cell tumor +7	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 1	NCT00744692 Background	Oct 2008 → Dec 2012	bone marrow failure syndrome, immunodeficiency disease, lysosomal storage disease, sickle cell disease +1	Duke University	Completed	No outcome recorded
Phase 1	NCT00104975 Background	Feb 2005 → May 2008	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm	Yale University	Completed	No outcome recorded
Phase 1	NCT00152100 Background	Feb 2004 → Aug 2007	severe combined immunodeficiency	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 1	NCT00943293 Background	May 2003 → Sep 2011	graft versus host disease, myeloproliferative neoplasm, plasma cell myeloma, premalignant hematological system disease	University of Chicago	Terminated	No outcome recorded
Phase 1	NCT00057005 Background	Feb 2003 → Oct 2009	leukemia	Baylor College of Medicine	Completed	No outcome recorded
Phase 1	NCT00586274 Background	Mar 2002 → Jul 2009	Fanconi anemia	Baylor College of Medicine	Terminated	No outcome recorded

Phase 1/222 trials
Phase 1/2	NCT06959771 Background	Jul 2025 → Oct 2027 expected	hyper-IgM syndrome type 1	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 1/2	NCT05607420 Background	Nov 2022 → Aug 2027 expected	B-cell non-Hodgkin lymphoma	Cellectis S.A.	Recruiting	No outcome recorded
Phase 1/2	NCT05463133 Background	Jul 2022 → Dec 2032 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 1/2	NCT05357482 Background	May 2022 → Jan 2026 overdue	beta thalassemia, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT04416984 Background	May 2020 → Feb 2029 expected	B-cell non-Hodgkin lymphoma	Allogene Therapeutics	Active not recruiting	No outcome recorded
Phase 1/2	NCT04150497 Background	Oct 2019 → Jun 2026 overdue	B-cell acute lymphoblastic leukemia	Cellectis S.A.	Recruiting	No outcome recorded
Phase 1/2	NCT03653338 Background	Aug 2018 → Aug 2026 overdue	Diamond-Blackfan anemia, beta-thalassemia major, sickle cell disease	Paul Szabolcs	Recruiting	No outcome recorded
Phase 1/2	NCT03500731 Background	Apr 2018 → Dec 2027 expected	chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis	Paul Szabolcs	Recruiting	No outcome recorded
Phase 1/2	NCT03128996 Background	Mar 2017 → Apr 2028 expected	bone marrow failure syndrome, metabolic disease, sickle cell disease	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT02629120 Comparator	Dec 2015 → Dec 2027 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Active not recruiting	No outcome recorded
Phase 1/2	NCT02059239 Background	Jun 2014 → Dec 2019	Hodgkins lymphoma, non-Hodgkin lymphoma	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 1/2	NCT01875237 Background	Dec 2013 → Mar 2017	leukemia, myeloproliferative neoplasm, plasma cell myeloma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT00692939 Background	Jun 2012 → Dec 2026 expected	Crohn disease	Paul Szabolcs	Recruiting	No outcome recorded
Phase 1/2	NCT01712945 Background	Jun 2012 → Aug 2017	multiple sclerosis	Cambridge University Hospitals NHS Foundation Trust	Terminated	No outcome recorded
Phase 1/2	NCT00943319 Background	Mar 2012 → Dec 2017	leukemia, plasma cell myeloma	University of Chicago	Completed	No outcome recorded
Phase 1/2	NCT01499888 Background	Nov 2011 → Sep 2028 expected	sickle cell disease	University of Illinois at Chicago	Active not recruiting	No outcome recorded
Phase 1/2	NCT01446484 Background	Oct 2011 → Nov 2014	end stage renal failure, kidney failure	Pirogov Russian National Research Medical University	Unknown	No outcome recorded
Phase 1/2	NCT00977691 Background	Dec 2009 → Aug 2018 overdue	sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT00626626 Background	May 2007 → Jan 2010	Hodgkins lymphoma, chronic myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma	Milton S. Hershey Medical Center	Terminated	No outcome recorded
Phase 1/2	NCT00183248 Background	Sep 2004 → Nov 2009	kidney failure	University of Miami	Completed	No outcome recorded
Phase 1/2	NCT00920972 Background	Dec 2001 → Dec 2026 expected	inherited hemoglobinopathy, metabolic disease	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT00281983 Background	Jun 2000 → Jul 2010	B-cell chronic lymphocytic leukemia	German CLL Study Group	Completed	No outcome recorded

Phase 241 trials
Phase 2	NCT07616154 Background	Sep 2026 → Sep 2034 expected	sickle cell disease	St. Jude Children's Research Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06084780 Background	Aug → Dec 2026 expected	pseudomyxoma peritonei, retroperitoneal cancer	Case Comprehensive Cancer Center	Not yet recruiting	No outcome recorded
Phase 2	NCT07284641 Background	May 2026 → May 2030 expected	DiGeorge syndrome, GATA2 deficiency with susceptibility to MDS/AML, Omenn syndrome, STAT3-related early-onset multisystem autoimmune disease +8	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT06358638 Background	Apr 2024 → Sep 2044 expected	sickle cell disease	Children's National Research Institute	Recruiting	No outcome recorded
Phase 2	NCT04971005 Comparator	Aug 2021 → Feb 2022	relapsing-remitting multiple sclerosis	University Medical Center Hamburg-Eppendorf	Terminated	No outcome recorded
Phase 2	NCT04339777 Comparator	Sep 2020 → Oct 2026 expected	T-cell immunodeficiency, autoimmune lymphoproliferative syndrome, common variable immunodeficiency	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT04362293 Background	Apr 2020 → Aug 2026	sickle cell disease	St. Jude Children's Research Hospital	Suspended	No outcome recorded
Phase 2	NCT04232085 Background	Feb 2020 → Dec 2027 expected	Fanconi anemia, Hoyeraal-Hreidarsson syndrome, bone marrow failure syndrome, dyskeratosis congenita and related telomere biology disorder +2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recruiting	No outcome recorded
Phase 2	NCT04018937 Background	Mar 2019 → Nov 2026 expected	sickle cell disease	Emory University	Active not recruiting	No outcome recorded
Phase 2	NCT03821610 Background	Nov 2018 → Oct 2025 overdue	acute lymphoblastic leukemia	University of Birmingham	Active not recruiting	No outcome recorded
Phase 2	NCT03630211 Background	Jul 2018 → Aug 2026 overdue	diffuse scleroderma, interstitial lung disease, pulmonary hypertension	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT03214354 Background	Jul 2017 → Jul 2028 expected	disease related to hematopoietic stem cell transplant, pure red-cell aplasia, sickle cell disease	University of Calgary	Recruiting	No outcome recorded
Phase 2	NCT02766465 Background	Mar 2017 → May 2023	sickle cell disease	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT02694770 Comparator	Jul 2016 → Sep 2017	acute graft versus host disease	AbGenomics B.V Taiwan Branch	Withdrawn	No outcome recorded
Phase 2	NCT02626715 Comparator	Sep 2015 → Apr 2023	acute myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome	Randy Windreich	Completed	No outcome recorded
Phase 2	NCT02497404 Background	Feb 2015 → Jun 2020	acute erythroid leukemia, myelodysplastic syndrome	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 2	NCT01962415 Background	Feb 2014 → Nov 2026 expected	bone marrow failure syndrome, hereditary anemia, immunodeficiency disease, inborn errors of metabolism +1	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT01679041 Background	Nov 2012 → Nov 2013	multiple sclerosis	Seah Lim M.D.	Terminated	No outcome recorded
Phase 2	NCT01889381 Background	Aug 2012 → Aug 2026 overdue	craniofacial and skeletal defects	Johns Hopkins University	Recruiting	No outcome recorded
Phase 2	NCT01596699 Background	May 2012 → Jun 2019	anemia, bone marrow failure syndrome, immune dysregulation, autoimmunity, and autoinflammation, immunodeficiency disease +2	University of California, San Francisco	Terminated	No outcome recorded
Phase 2	NCT01518153 Background	Feb 2012 → Aug 2014	leukemia, myeloproliferative neoplasm, plasma cell myeloma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT01256398 Background	Dec 2010 → Nov 2017	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01043640 Background	Dec 2009 → Jun 2015	Hurler syndrome, Krabbe disease, adrenoleukodystrophy, alpha-mannosidosis +4	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00986557 Background	Sep 2009 → Aug 2013	graft versus host disease	University Hospital Birmingham	Unknown	No outcome recorded
Phase 2	NCT00871546 Comparator	Mar 2009 → Dec 2010	B-cell chronic lymphocytic leukemia, mantle cell lymphoma	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00720447 Background	Nov 2008 → Nov 2010	lymphoma	Cancer Research UK	Unknown	No outcome recorded
Phase 2	NCT00745420 Background	Aug 2008 → Jul 2015	sickle cell disease	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT00668564 Background	Mar 2008 → Feb 2010	Hurler syndrome, Krabbe disease, Niemann-Pick disease type B, Niemann-Pick disease type C +5	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00638820 Background	Sep 2007 → May 2008	osteopetrosis	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00536978 Background	Sep 2007 → Nov 2010	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00441025 Comparator	Sep 2006 → Aug 2009	peripheral T-cell lymphoma, not otherwise specified	Mahidol University	Terminated	No outcome recorded
Phase 2	NCT00383448 Background	Sep 2006 → Sep 2014	GM1 gangliosidosis, Krabbe disease, Sandhoff disease, Tay-Sachs disease +5	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00578942 Background	May 2005 → Apr 2013	leukemia, myelodysplastic syndrome, plasma cell myeloma	David Rizzieri, MD	Completed	No outcome recorded
Phase 2	NCT00818961 Background	May 2005 → Mar 2011	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Northside Hospital, Inc.	Terminated	No outcome recorded
Phase 2	NCT00153985 Background	Mar 2004 → Mar 2008	sickle cell disease, thalassemia	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00578643 Background	Mar 2004 → Jul 2017	chronic granulomatous disease	Baylor College of Medicine	Completed	No outcome recorded
Phase 2	NCT00309270 Background	Feb 2003 → Apr 2010	—	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 2	NCT00176865 Comparator	Aug 2002 → Aug 2012	Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00578903 Background	Feb 2002 → Jul 2012	aplastic anemia	Baylor College of Medicine	Terminated	No outcome recorded
Phase 2	NCT00040469 Background	Aug 2000 → Nov 2003	sickle cell disease, thalassemia	Baylor College of Medicine	Terminated	No outcome recorded
Phase 2	NCT00368355 Background	Apr 2000 → Nov 2015	X-linked lymphoproliferative syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +2	Baylor College of Medicine	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT00775931 Comparator	Aug 2008 → Jun 2013	osteopetrosis	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT00455312 Background	Aug 2007 → Mar 2015	aplastic anemia, dyskeratosis congenita	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT01019876 Comparator	Sep 2002 → Sep 2021	Fanconi anemia, bone marrow failure syndrome, osteopetrosis, severe combined immunodeficiency	Columbia University	Completed	No outcome recorded
Phase 34 trials
Phase 3	NCT04047628 Background	Dec 2019 → Oct 2026 expected	relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 3	NCT03477500 Comparator	Mar 2018 → Nov 2026 expected	multiple sclerosis	Haukeland University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT01877837 Background	Jun 2011 → Sep 2021	sickle cell disease	Hackensack Meridian Health	Completed	No outcome recorded
Phase 3	NCT00564512 Comparator	Nov 2007 → Jan 2009	leukemia	French Innovative Leukemia Organisation	Completed	No outcome recorded
Phase 44 trials
Phase 4	NCT01046955 Comparator	Nov 2005 → Apr 2007	end stage renal failure	University of Miami	Completed	No outcome recorded
Phase 4	NCT00246129 Comparator	Oct 2005 → Jun 2011	kidney failure	EMagnusson	Completed	No outcome recorded
Phase 4	NCT00166712 Comparator	Apr 2005 → Apr 2010	chronic transplant rejection	Northwestern University	Terminated	No outcome recorded
Phase 4	NCT00331162 Comparator	Feb 2005 → Nov 2011	transplant rejection	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase not applicable7 trials
—	NCT02529839 Background	Oct 2015 → Oct 2017	multiple sclerosis	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT02162420 Background	Jan 2015 → Aug 2024	aplastic anemia, dyskeratosis congenita	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT01626092 Background	Jul 2012 → Nov 2013	lysosomal storage disease, peroxisomal disease	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT00578539 Background	Oct 2007 → May 2013	Hodgkins lymphoma, leukemia, myeloproliferative neoplasm, non-Hodgkin lymphoma	Baylor College of Medicine	Terminated	No outcome recorded
—	NCT02711202 Comparator	Jan 2007 → Mar 2009	—	Institute for Clinical and Experimental Medicine	Completed	No outcome recorded
—	NCT00578344 Background	Jul 2005 → Jul 2012	sickle cell-hemoglobin c disease syndrome	Tami D. John	Terminated	No outcome recorded
—	NCT00578292 Background	Feb 2004 → May 2016	thalassemia	Baylor College of Medicine	Terminated	No outcome recorded

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 328 sources stand behind the page.

Field	Value	Cited text
Known as	alemtuzumab	“This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine...” NCT00943592 ↗ 246 “Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections, were enrolled in a novel RIC protocol consisting of hydroxyurea,...” PMID 24296492 ↗ Dec 2013 “After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were...” NCT00147901 ↗ “This is an open-label, single arm, proof-of-principle study of Campath (also known as alemtuzumab) maintenance therapy administered subcutaneously at varying intervals for up to 1 year.” NCT00587847 ↗ “Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1.” NCT01049854 ↗ “Alemtuzumab (Campath®) is a humanized monoclonal antibody to CD52 that is FDA approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)” NCT00331162 ↗ “Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively” NCT00745420 ↗ “CAMPATH-1H (Alemtuzumab) is a recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52;” NCT00533923 ↗ “conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗ “Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells.” NCT01909245 ↗ “Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy.” NCT01459107 ↗ “The transplant conditioning regimen will include fludarabine, melphalan, and alemtuzumab starting at Day -14 (Flu/Mel/Alem).” NCT01998633 ↗ “Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy.” NCT01889381 ↗ “Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.” PMID 18510632 ↗ Jul 2008 “Campath-1H (alemtuzumab) induction was used for renal transplantation in combination with sirolimus as immunosuppression.” PMID 17018123 ↗ Nov 2006 “methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept” NCT02694770 ↗ “Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0” NCT01679860 ↗ “Both monoclonal (Alemtuzumab) and polyclonal T-depletion protocols carry risks and benefits.” NCT00354120 ↗ “4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours” NCT00597714 ↗ “Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22)” NCT02165007 ↗ “Phase A: Escalating Doses of alemtuzumab (Campath) Alone” NCT00086580 ↗ “Campath (alemtuzumab) - drug class: monoclonal antibody” NCT02626715 ↗ “alemtuzumab (Campath®, Lemtrada®)” NCT04047628 ↗ “Lemtrada (alemtuzumab)” NCT03535298 ↗ “CAMPATH (alemtuzumab)” NCT00113048 ↗ “Alemtuzumab (Campath)” NCT01050855 ↗ “alemtuzumab (3mg IV)” NCT03128996 ↗ “* Alemtuzumab” NCT02179359 ↗ “* Alemtuzumab” NCT02171104 ↗ “Alemtuzumab” NCT00153985 ↗ NCT00281983 ↗ NCT01392079 ↗ NCT00057967 ↗ NCT01821781 ↗ NCT01875237 ↗ NCT00410657 ↗ NCT03579875 ↗ NCT00079768 ↗ NCT03630211 ↗ NCT00143065 ↗ NCT01518153 ↗ NCT00006390 ↗ NCT00977691 ↗ NCT01082939 ↗ NCT02105766 ↗ NCT00336206 ↗ NCT00858117 ↗ NCT00669318 ↗ NCT01982175 ↗ NCT00555048 ↗ NCT00520130 ↗ NCT00562068 ↗ NCT00771602 ↗ NCT01191749 ↗ NCT00781781 ↗ NCT00292760 ↗ NCT00183248 ↗ NCT00562328 ↗ NCT03077542 ↗ NCT03214354 ↗ NCT00408447 ↗ NCT00907036 ↗ NCT01659606 ↗ NCT00214214 ↗ NCT00908180 ↗ NCT00871546 ↗ NCT00085449 ↗ NCT01333358 ↗ NCT04362293 ↗ NCT01186640 ↗ NCT06872333 ↗ NCT00337519 ↗ NCT00553098 ↗ NCT00161590 ↗ NCT00098670 ↗ NCT00073879 ↗ NCT03302754 ↗ NCT00725231 ↗ NCT02435901 ↗ NCT00983528 ↗ NCT00773149 ↗ NCT02689453 ↗ NCT00051701 ↗ NCT00646854 ↗ NCT01877837 ↗ NCT00074282 ↗ NCT00050778 ↗ NCT01652092 ↗ NCT00565773 ↗ NCT01208337 ↗ NCT05357482 ↗ NCT00081068 ↗ NCT00565981 ↗ NCT03135249 ↗ NCT00895739 ↗ NCT07599176 ↗ NCT01436305 ↗ NCT00618540 ↗ NCT00162851 ↗ NCT00566696 ↗ NCT00061048 ↗ NCT00634881 ↗ NCT00525603 ↗ NCT00436904 ↗ NCT00086775 ↗ NCT02867800 ↗ NCT06358638 ↗ NCT01213329 ↗ NCT03653338 ↗ NCT00278213 ↗ NCT00345345 ↗ NCT01042509 ↗ NCT01361711 ↗ NCT00276809 ↗ NCT00986557 ↗ NCT00316810 ↗ NCT00078559 ↗ NCT00001984 ↗ NCT02653196 ↗ NCT00240994 ↗ NCT00105235 ↗ NCT00104975 ↗ NCT00330252 ↗ NCT00157274 ↗ NCT00525876 ↗ NCT04339777 ↗ NCT00472433 ↗ NCT01679041 ↗ NCT02255656 ↗ NCT01182675 ↗ NCT00206726 ↗ NCT00548405 ↗ NCT02162420 ↗ NCT00046683 ↗ NCT01712945 ↗ NCT05384756 ↗ NCT00274976 ↗ NCT00004857 ↗ NCT03587272 ↗ NCT01019876 ↗ NCT02472054 ↗ NCT00021151 ↗ NCT03500731 ↗ NCT00129753 ↗ NCT00061568 ↗ NCT01596699 ↗ NCT03821610 ↗ NCT00177138 ↗ NCT04232085 ↗ NCT00453193 ↗ NCT00195624 ↗ NCT03910452 ↗ NCT03421756 ↗ NCT01395316 ↗ NCT04018937 ↗ NCT00453427 ↗ NCT01962415 ↗ NCT00923182 ↗ NCT00061945 ↗ NCT00637390 ↗ NCT00454480 ↗ NCT00069238 ↗ NCT07616154 ↗ NCT01269385 ↗ NCT01172418 ↗ NCT00077961 ↗ NCT00951457 ↗ NCT01729494 ↗ NCT00109993 ↗ NCT00040846 ↗ NCT00947388 ↗ NCT00328198 ↗ NCT01757574 ↗ NCT00578643 ↗ NCT00495755 ↗ NCT00166712 ↗ NCT00175266 ↗ NCT00175253 ↗ NCT02629120 ↗ NCT02497404 ↗ NCT00930553 ↗ NCT01013961 ↗ NCT00692939 ↗ NCT00383448 ↗ NCT00038844 ↗ NCT04154735 ↗ NCT01806337 ↗ NCT00530348 ↗ NCT01465334 ↗ NCT00930605 ↗ NCT05501756 ↗ NCT00997386 ↗ NCT01120028 ↗ NCT01624714 ↗ NCT06959771 ↗ NCT02419378 ↗ NCT00027560 ↗ NCT00260689 ↗ NCT00626626 ↗ NCT00113269 ↗ NCT00301834 ↗ NCT00775632 ↗ NCT03132584 ↗ NCT02205489 ↗ NCT00504491 ↗ NCT01625351 ↗ NCT00582894 ↗ NCT00217594 ↗ NCT04971005 ↗ NCT00363090 ↗ NCT06084780 ↗ NCT01005576 ↗ NCT00935792 ↗ NCT02678143 ↗ NCT02583594 ↗ NCT00818961 ↗ NCT00458523 ↗ NCT02013375 ↗ NCT00262925 ↗ NCT03504241 ↗ NCT00199030 ↗ NCT00089349 ↗ NCT01499888 ↗ NCT02385110 ↗ NCT02529839 ↗ NCT01408342 ↗ NCT01446484 ↗ NCT00230282 ↗ NCT00323323 ↗ NCT02061800 ↗ NCT00152100 ↗ NCT02059239 ↗ NCT00118352 ↗ NCT03477500 ↗ NCT02766465 ↗ NCT00749112 ↗ NCT00441025 ↗ NCT00698685 ↗ NCT01256398 ↗ NCT00801931 ↗ NCT00720447 ↗ NCT05463133 ↗ NCT01405807 ↗ NCT00800943 ↗ NCT03182426 ↗ NCT00881556 ↗ NCT03989466 ↗
Known as	Alemtuzumab (Campath)	“Alemtuzumab (Campath®)” NCT00997386 ↗ 1 “Alemtuzumab (Campath)” NCT01877837 ↗
Known as	alemtuzumab (Campath, Lemtrada)	“alemtuzumab (Campath®, Lemtrada®)” NCT04047628 ↗
Known as	Alemtuzumab (genetical recombination)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201587 ↗
Known as	ALLO-647	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04093596 ↗ 5 NCT04696731 ↗ NCT05714345 ↗ NCT04416984 ↗ NCT03939026 ↗ NCT05000450 ↗
Known as	Campath	“Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark])...” PMID 20659956 ↗ Jul 2010 38 “To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone...” NCT00161590 ↗ “This study will examine the safety and effectiveness of alemtuzumab (Campath® (Registered Trademark)) for improving muscle strength in patients with sporadic inclusion body...” NCT00079768 ↗ “CAMPATH (alemtuzumab, MABCAMPATH, CAMPATH) administered intravenously (IV) once a week as treatment for relapsing or refractory non-Hodgkin's lymphoma (NHL).” NCT00051701 ↗ “Alemtuzumab (Campath®) is a humanized monoclonal antibody to CD52 that is FDA approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)” NCT00331162 ↗ “conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗ “Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells.” NCT01909245 ↗ “Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days” NCT00206726 ↗ “Alemtuzumab is approved and sold under the brand names Campath and MabCampath to treat some types of leukemia.” NCT01333358 ↗ “Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52.” NCT03302754 ↗ “An antibody therapeutic, Alemtuzumab (also know as Campath), that kills cells that make the CD52 protein” NCT00637390 ↗ “Alemtuzumab (Campath ), Sirolimus (Rapamune ), Cyclophosphamide (Cytoxan ), and pentostatin (Nipent )” NCT03077542 ↗ “Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.” NCT00345345 ↗ “consisting of alemtuzumab (Campath) for primary evaluation of overall response and time to relapse.” NCT00157274 ↗ “alemtuzumab (Campath)) 10 mg/m^2 total dose divided over 3 days by subcutaneous injection” NCT06959771 ↗ “Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil” NCT00046683 ↗ “an antibody (protein) called alemtuzumab or Campath” NCT00775632 ↗ “Pentostatin (Nipent®) and Alemtuzumab (Campath®)” NCT00698685 ↗ “Alemtuzumab (Campath)” NCT00217594 ↗ “Alemtuzumab (Campath)” NCT00495755 ↗ “Alemtuzumab (Campath)” NCT01050855 ↗ “CAMPATH (alemtuzumab)” NCT00077961 ↗ NCT01030900 ↗ NCT00683046 ↗ NCT00684255 ↗ NCT00246129 ↗ NCT00564512 ↗ NCT00047060 ↗ NCT00004143 ↗ NCT00176852 ↗ NCT07015684 ↗ NCT00578903 ↗ NCT00579111 ↗ NCT00113048 ↗ NCT00943319 ↗ NCT00943293 ↗ NCT00416884 ↗ NCT00462332 ↗ NCT00587847 ↗
Known as	CAMPATH 1H	“This protocol will test a humanized monoclonal antibody known as Campath-1H for its ability to induce a state of permanent allograft acceptance, or tolerance, when administered...” NCT00001984 ↗ 70 “To translate IL-15-mediated increases in NK cells, we investigated combination therapy of IL-15 with anticancer monoclonal antibodies including rituximab in mouse models of...” PMID 32508818 ↗ May 2020 “This study investigated the efficacy, safety, and clinical benefit of alemtuzumab (Campath-1H) for patients with relapsed or refractory B-cell chronic lymphocytic leukemia...” PMID 11986207 ↗ May 2002 “The purpose of this study is to evaluate the use of alemtuzumab (Campath-1H) for induction therapy in kidney and pancreas transplantation compared to our standard of care,...” NCT00331162 ↗ “Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52, a cell surface protein present at high density on most normal and malignant B and T lymphocytes.” NCT00930605 ↗ “Campath-1H (alemtuzumab) given subcutaneously during post-remission intensification treatment of adults with acute lymphoblastic leukemia (ALL).” NCT00061945 ↗ “In addition, a monoclonal antibody called Campath-1H will be given to target lymphocytes, including those that have become cancerous.” NCT00047060 ↗ “CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body.” NCT00040469 ↗ “Our group has combined the above combination of fludarabine and cyclophosphamide with the antibody CAMPATH 1H.” NCT00580034 ↗ “Our group has combined the above combination of fludarabine and cyclophosphamide with the antibody CAMPATH 1H.” NCT00578942 ↗ “A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL” NCT00858117 ↗ “Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma” NCT00193466 ↗ “Alemtuzumab (Campath-1H) is a humanized rat monoclonal antibody that binds to CD52 and is cytotoxic.” NCT00061048 ↗ “5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.” NCT00578942 ↗ “5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours” NCT00580034 ↗ “Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0” NCT01679860 ↗ “Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52” NCT00441025 ↗ “Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.” PMID 19454532 ↗ May 2009 “Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.” NCT00578344 ↗ “CAMPATH-1H is an antibody against certain types of blood cells.” NCT00578539 ↗ “The third MAb is Campath 1H, a humanized rat anti-CD52 MAb.” NCT00590460 ↗ “The investigational drug is alemtuzumab (Campath-1H).” NCT00453427 ↗ “Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours” NCT00638820 ↗ “incorporating the lymphodepleting MAb CAMPATH-1H” NCT00048412 ↗ “Alemtuzumab (CAMPATH 1H) associated to G-CSF” NCT00773149 ↗ “Day -22: Campath-1H 3 mg IV or SQ” NCT00920972 ↗ “Campath 1H® (Alemtuzumab)” NCT00214214 ↗ “Biological: Campath-1h” NCT00578539 ↗ “Drug: Campath-1h” NCT00278512 ↗ “Drug: Campath 1H” NCT00176865 ↗ NCT00142181 ↗ NCT00057005 ↗ NCT00056966 ↗ NCT00071396 ↗ NCT00426517 ↗ NCT00056979 ↗ NCT00668564 ↗ NCT00214266 ↗ NCT00685061 ↗ NCT00282412 ↗ NCT00058825 ↗ NCT00048412 ↗ NCT00048399 ↗ NCT00102661 ↗ NCT00278512 ↗ NCT01043640 ↗ NCT00309270 ↗ NCT02701517 ↗ NCT00069992 ↗ NCT00619528 ↗ NCT00681343 ↗ NCT01046955 ↗ NCT00578292 ↗ NCT00166556 ↗ NCT00579137 ↗ NCT00455312 ↗ NCT00579592 ↗ NCT00038883 ↗ NCT00167661 ↗ NCT00505921 ↗ NCT01626092 ↗ NCT00536978 ↗ NCT00775931 ↗ NCT00458250 ↗ NCT00590460 ↗ NCT00065260 ↗ NCT00586274 ↗ NCT00226512 ↗ NCT00368355 ↗ NCT00533923 ↗ NCT00365846 ↗
Known as	Campath mabcampath	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201587 ↗
Known as	Campath mabcampath, lemtrada	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201587 ↗
Known as	Campath-1H (Alemtuzumab)	“Campath-1H (Alemtuzumab)” NCT01172418 ↗
Known as	Campath-IH	“Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.” NCT00142181 ↗ 1 “Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17” NCT02435901 ↗
Known as	CLLS52	“Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab” NCT03190278 ↗ 2 NCT05607420 ↗ NCT04150497 ↗
Known as	GZ-402673	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201587 ↗
Known as	LDP-03	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201587 ↗
Known as	Lemtrada	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201587 ↗
Known as	Lemtrada (alemtuzumab)	“Lemtrada (alemtuzumab)” NCT03535298 ↗
Known as	Mab- Campath (Alemtuzumab)	“Mab- Campath (Alemtuzumab)” NCT01679860 ↗
Known as	MabCampath	“CAMPATH (alemtuzumab, MABCAMPATH, CAMPATH) administered intravenously (IV) once a week as treatment for relapsing or refractory non-Hodgkin's lymphoma (NHL).” NCT00051701 ↗ 6 “Alemtuzumab is approved and sold under the brand names Campath and MabCampath to treat some types of leukemia.” NCT01333358 ↗ “Consolidation Therapy With Alemtuzumab (MabCampath®) in Patients With Chronic Lymphocytic Leukemia” NCT00634881 ↗ “Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil” NCT00046683 ↗ “the monoclonal antibody MabCampath® (alemtuzumab)” NCT00646854 ↗ “Alemtuzumab (MabCampath)” NCT00199030 ↗ NCT02711202 ↗
Known as	MabCampath-1h	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01307332 ↗
Action	Deplete	“Its administration temporarily depletes mature lymphocytes and some monocytes” NCT00001984 ↗
Modality	Monoclonal antibody	“This protocol will test a humanized monoclonal antibody known as Campath-1H” NCT00001984 ↗
Route	Intravenous	“Alemtuzumab was administered intravenously” NCT00001984 ↗
Target	CD52	“The humanized anti-CD52 monoclonal antibody alemtuzumab” PMID 19863336 ↗ Oct 2009